ClinicalTrials.gg
Active, not recruitingNCT04859985Updated Jan 22, 2026

The SELUTION DeNovo Study

An interventional study of SELUTION SLR and DES in Coronary Artery Disease, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 62 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.

Enrollment
19th of 248
3,326 · median 265
Started
2021
with 10 others
No phase
128 of 365
18 open now
Primary completion
2025-09
later than 19 of 70 live
Registered
306th of 365
by date

Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 19th largest by enrollment of the 248 interventional ones that give a count, is one of 11 that started in 2021, is one of 128 with no phase, reaches primary completion later than 19 of the 70 other live ones, and was the 306th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Coronary Artery Disease with a site in Germany, or all of them as a file.
02

Study summary

A Prospective Randomized, Multi-centre, International, Open Label, Clinical trial comparing the Selution DEB strategy versus DES strategy.

Read the detailed description

Randomized, multi-centre, international, open label, clinical trial. Patients meeting eligibility criteria will be randomized 1:1 to treatment of all lesions of the identified trial target vessel(s) with either the SELUTION SLR DEB or DES.

Patients randomized to the SELUTION SLR DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION DEB group (intention to treat analysis).

Patients randomized to the DES arm will receive treatment using any CE-marked DES, as per standard institutional practice. Patients with failure to deliver DES will be first treated by provisional DEB using the SELUTION DEB, and failing that, with any other device deemed appropriate.

Staged procedures are allowed if they are planned less than 45 days after the index procedure and are done according to the initial treatment allocation for all trial target vessels (DEB if DEB arm, DES if DES arm).

The study will test:

  1. for non-inferiority of a DEB plus provisional DES treatment strategy versus a systematic DES strategy with respect to the primary endpoint of TVF at 12 months.
  2. for non-inferiority of a DEB plus provisional DES treatment strategy versus a systematic DES strategy with respect to the primary endpoint of TVF at 5 years. If non-inferiority is then established, superiority of the DEB strategy with TVF as an endpoint will be tested.

All Patients will be followed for clinical outcomes at 30 days, 6 months, 1 2, 3, 4 and 5 years.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Drug Eluting Balloon
  • Coronary
  • De Novo coronary lesions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all the following criteria to participate in the trial:

  • Subject age is ≥ 18 years (or 21 according to countries legal age)
  • Female subjects of have a negative pregnancy test ≤7 days before the procedure or are using a device or drug.
  • Documented angina and/or positive functional testing or unstable angina or stabilized NSTEMI presentation.
  • >1 year
  • Written by the subject or her/his legally authorized representative for participation in the study
  • One or more native target vessel (LAD, LCX or RCA) is considered to require intervention and is suitable for treatment of all lesions with either DEB + provisional stenting or with DES and is identified as such.
  • The number of trial target lesions is not limited, but in the operator's opinion, if the subject is randomized to the DEB arm, the likelihood of the subject requiring provisional stenting of any of the identified trial target lesions is \< 30%, and if randomized to the systematic DES arm, all lesions are considered amenable to stenting.
  • All target lesions: diameter between 2.0 and 5 mm, and diameter stenosis >50% and \<100% with distal flow at least TIMI 2

Exclusion Criteria:

Age \< 18 years (or 21 according to countries legal age)

  • Subject is pregnant or breast-feeding
  • Definite or suspected clinically active covid-19 infection
  • Subject is under judicial protection, tutorship or curatorship (for France only)
  • Subject is unable to fully comply with the study protocol
  • to dual antiplatelet therapy, sirolimus or its analogues
  • Presentation with STEMI
  • Presentation with NSTEMI and ongoing chest pain or hemodynamic instability
  • Presentation with Killip III (pulmonary oedema) or IV (cardiogenic shock)
  • Chronic class III or IV heart failure prior to index PCI
  • Known \< 30% prior to index PCI
  • Previous PCI of a trial target vessel at any time
  • Previous PCI of a non-trial target vessel within 30 days
  • Trial target lesion located in the left main or any arterial or venous graft
  • Trial target lesion is chronic total occlusion (CTO) or in-stent restenosis (ISR)
  • Subject considered not able to tolerate at least 30 seconds of coronary occlusion for each trial target lesion
  • RVD of trial target lesion > 5mm
  • Planned major surgery within one month following the procedure
  • Currently participating in another drug or device study that has not completed primary endpoint follow-up
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,326 participants (actual)

Study arms

  • Experimental
    SELUTION SLR DEB

    Device: SELUTION SLR DEB. For patients randomized to the DEB strategy, all target lesions should be treated with DEB after appropriate lesion preparation, but provisional DES implantation is acceptable if the angiographic result is considered insufficient either after lesion preparation of after DEB treatment (poor flow, dissection type C or higher, residual stenosis \> 30%). For bifurcation lesions, when both main and side- branch are considered to require treatment, a DEB should be used for both.

    Device: SELUTION SLR

  • Other
    DES

    Device: Drug Eluting Stent. For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.

    Device: DES

Interventions

  • DeviceSELUTION SLR

    Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).

  • DeviceDES

    For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.

06

What researchers measure

Primary outcomes

  1. TVF

    \- TVF (cardiac death, target-vessel related myocardial infarction (MI) or clinically driven target vessel revascularization (cd-TVR) at 1 year

    Time frame: 1 year after treatment

  2. TVF

    \- TVF (cardiac death, target-vessel related myocardial infarction (MI) or clinically driven target vessel revascularization (cd-TVR)) at 5 years

    Time frame: 5 years after treatment

Secondary outcomes

  1. Death or any MI

    Cardiac death, non-cardiac death, or any Myocardial Infarction

    Time frame: 30 days after treatment

  2. CD-TVR

    Clinically driven - Target Vessel Revascularization

    Time frame: 30 days after treatment

  3. TVF

    Target Vessel Failure

    Time frame: 2, 3, 4, 5 years after treatment

  4. Any revascularization

    1. Target lesion revascularization (TLR) - any and clinically driven 2. Target vessel revascularization (TVR) - any and clinically driven 3. A new lesion revascularization in a target vessel 4. Non-Target vessel revascularization

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  5. Myocardial Infarction (MI)

    1. Peri-procedural MI 2. Target-vessel MI 3. Non-target-vessel MI 4. MI type (1 to 5) according to the 4th universal definition

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  6. Composite of cardiac death or target vessel MI

    Composite of cardiac death or target vessel Myocardial Infarction

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  7. All-cause mortality

    * Cardiac mortality * Non-cardiac mortality

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  8. Patient-oriented ARC-2 composite endpoint

    1. All-cause mortality 2. Any stroke 3. Any MI (includes non-target vessel territory) 4. Any revascularization

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  9. Site-reported stroke

    Site-reported stroke

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  10. Site-reported BARC 3-5 Bleeding

    Site-reported BARC (Bleeding Academic Research Consortium ) 3-5 Bleeding

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  11. Cost-effectiveness of DEB vs. DES after 12 months in selected countries

    Total costs of materials used during treatment

    Time frame: 1, 2, 3, 4 and 5 years after treatment

  12. Cost-effectiveness of DEB vs. DES after 12 months in selected countries

    Time of procedure. Total minutes from patient introducer introduction until removal

    Time frame: 1, 2, 3, 4 and 5 years after treatment

  13. Cost-effectiveness of DEB vs. DES after 12 months in selected countries

    Total hospitalization days per procedure.

    Time frame: 1, 2, 3, 4 and 5 years after treatment

  14. Net clinical benefit, a combination of freedom from TVF and/or BARC 3-5 bleeding

    Net clinical benefit, a combination of freedom from (Target Vessel Failure) TVF and/or BARC 3-5 bleeding

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  15. Device success

    Device success defined as achievement of a final residual diameter stenosis of \< 30% (site-reported), using the assigned device only

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  16. Lesion success

    Lesion success defined as achievement of \< 30% residual stenosis (site-reported), using any PCI method

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

  17. Procedure success

    Procedure success defined as achievement of a final diameter stenosis of \< 30% (site-reported) using any PCI method, without the occurrence of death, MI, or repeat target vessel revascularization during hospital stay

    Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment

07

Study locations

62 sites
08

References and documents

Publications

  • Spaulding C, Krackhardt F, Bogaerts K, Abdelaal E, Alfonso F, Briguori C, Bruch L, Cruden N, Den Hartog AW, Garot P, Godin M, Hildick-Smith D, Johnson T, Ladwiniec A, Linke A, Maart CA, Mashayekhi K, Meier P, Meunier L, Morgan K, O'Kane P, Puymirat E, Rissanen TT, Sabate M, Schmitz T, Toth GG, Trevelyan J, Wanczura P, Marcus W, Wykrzykowska JJ, Urban P, Eccleshall S; SELUTION DeNovo Investigators. Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial. Circulation. 2026 Jun 15. doi: 10.1161/CIRCULATIONAHA.126.079033. Online ahead of print. PubMed 42290366 ↗
  • Spaulding C, Krackhardt F, Bogaerts K, Urban P, Meis S, Morice MC, Eccleshall S. Comparing a strategy of sirolimus-eluting balloon treatment to drug-eluting stent implantation in de novo coronary lesions in all-comers: Design and rationale of the SELUTION DeNovo Trial. Am Heart J. 2023 Apr;258:77-84. doi: 10.1016/j.ahj.2023.01.007. Epub 2023 Jan 13. PubMed 36642225 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Sep 2025, 52 months.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 52 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Apr 26, 2021
StartActual
May 15, 2021
Primary completionActual
Sep 15, 2025
CompletionEst.
Oct 31, 2030
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04859985
Lead sponsor
M.A. Med Alliance S.A.
Responsible party
Sponsor
First posted
Apr 26, 2021
Start date
May 15, 2021
Primary completion
Sep 15, 2025
Completion
Oct 31, 2030 (estimated)
Last update
Jan 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion